Global Oral Hypoglyceimic Agents (OHAs) Market Insights, Forecast to 2025

Description

Oral hypoglycemic agents (OHAs) are a group of drugs used to help reduce the amount of sugar present in the blood. They are not insulin, but they stimulate the pancreas to produce insulin.
At present, China is a country with the most populous victims of diabetes, SO, China will witness a huge potential in the OHAS market.
The global Oral Hypoglyceimic Agents (OHAs) market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oral Hypoglyceimic Agents (OHAs) market based on company, product type, end user and key regions.

This report studies the global market size of Oral Hypoglyceimic Agents (OHAs) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oral Hypoglyceimic Agents (OHAs) in these regions.
This research report categorizes the global Oral Hypoglyceimic Agents (OHAs) market by top players/brands, region, type and end user. This report also studies the global Oral Hypoglyceimic Agents (OHAs) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
GlaxoSmithKline
Bayer
Bristol-Myers Squibb
Novonordisk
Sanofi-Aventis
Servier
Huadong Medicine
Wanbang Biopharmaceuticals
Double-Crane Pharmaceutical
Guangzhou Pharmaceutical

Market size by Product
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Market size by End User
Hospitals and Clinics
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Oral Hypoglyceimic Agents (OHAs) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Oral Hypoglyceimic Agents (OHAs) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Oral Hypoglyceimic Agents (OHAs) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Oral Hypoglyceimic Agents (OHAs) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Oral Hypoglyceimic Agents (OHAs) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Oral Hypoglyceimic Agents (OHAs) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

TABLE OF CONTENT

Table of Contents

1 Study Coverage
1.1 Oral Hypoglyceimic Agents (OHAs) Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Oral Hypoglyceimic Agents (OHAs) Market Size Growth Rate by Product
1.4.2 Sulfonylureas
1.4.3 Metformin
1.4.4 Thiazolidinediones
1.4.5 Alpha-Glucosidase Inhibitors
1.5 Market by End User
1.5.1 Global Oral Hypoglyceimic Agents (OHAs) Market Size Growth Rate by End User
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Oral Hypoglyceimic Agents (OHAs) Market Size
2.1.1 Global Oral Hypoglyceimic Agents (OHAs) Revenue 2014-2025
2.1.2 Global Oral Hypoglyceimic Agents (OHAs) Sales 2014-2025
2.2 Oral Hypoglyceimic Agents (OHAs) Growth Rate by Regions
2.2.1 Global Oral Hypoglyceimic Agents (OHAs) Sales by Regions
2.2.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Oral Hypoglyceimic Agents (OHAs) Sales by Manufacturers
3.1.1 Oral Hypoglyceimic Agents (OHAs) Sales by Manufacturers
3.1.2 Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Manufacturers
3.1.3 Global Oral Hypoglyceimic Agents (OHAs) Market Concentration Ratio (CR5 and HHI)
3.2 Oral Hypoglyceimic Agents (OHAs) Revenue by Manufacturers
3.2.1 Oral Hypoglyceimic Agents (OHAs) Revenue by Manufacturers (2014-2019)
3.2.2 Oral Hypoglyceimic Agents (OHAs) Revenue Share by Manufacturers (2014-2019)
3.3 Oral Hypoglyceimic Agents (OHAs) Price by Manufacturers
3.4 Oral Hypoglyceimic Agents (OHAs) Manufacturing Base Distribution, Product Types
3.4.1 Oral Hypoglyceimic Agents (OHAs) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Oral Hypoglyceimic Agents (OHAs) Product Type
3.4.3 Date of International Manufacturers Enter into Oral Hypoglyceimic Agents (OHAs) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Oral Hypoglyceimic Agents (OHAs) Sales by Product
4.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue by Product
4.3 Oral Hypoglyceimic Agents (OHAs) Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Oral Hypoglyceimic Agents (OHAs) Breakdown Data by End User

6 North America
6.1 North America Oral Hypoglyceimic Agents (OHAs) by Countries
6.1.1 North America Oral Hypoglyceimic Agents (OHAs) Sales by Countries
6.1.2 North America Oral Hypoglyceimic Agents (OHAs) Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Oral Hypoglyceimic Agents (OHAs) by Product
6.3 North America Oral Hypoglyceimic Agents (OHAs) by End User

7 Europe
7.1 Europe Oral Hypoglyceimic Agents (OHAs) by Countries
7.1.1 Europe Oral Hypoglyceimic Agents (OHAs) Sales by Countries
7.1.2 Europe Oral Hypoglyceimic Agents (OHAs) Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Oral Hypoglyceimic Agents (OHAs) by Product
7.3 Europe Oral Hypoglyceimic Agents (OHAs) by End User

8 Asia Pacific
8.1 Asia Pacific Oral Hypoglyceimic Agents (OHAs) by Countries
8.1.1 Asia Pacific Oral Hypoglyceimic Agents (OHAs) Sales by Countries
8.1.2 Asia Pacific Oral Hypoglyceimic Agents (OHAs) Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Oral Hypoglyceimic Agents (OHAs) by Product
8.3 Asia Pacific Oral Hypoglyceimic Agents (OHAs) by End User

9 Central & South America
9.1 Central & South America Oral Hypoglyceimic Agents (OHAs) by Countries
9.1.1 Central & South America Oral Hypoglyceimic Agents (OHAs) Sales by Countries
9.1.2 Central & South America Oral Hypoglyceimic Agents (OHAs) Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Oral Hypoglyceimic Agents (OHAs) by Product
9.3 Central & South America Oral Hypoglyceimic Agents (OHAs) by End User

10 Middle East and Africa
10.1 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) by Countries
10.1.1 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Sales by Countries
10.1.2 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) by Product
10.3 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) by End User

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Company Business Overview
11.1.3 Pfizer Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Pfizer Oral Hypoglyceimic Agents (OHAs) Products Offered
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 Company Business Overview
11.2.3 GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.2.4 GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Products Offered
11.2.5 GlaxoSmithKline Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Company Business Overview
11.3.3 Bayer Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Bayer Oral Hypoglyceimic Agents (OHAs) Products Offered
11.3.5 Bayer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Company Business Overview
11.4.3 Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Products Offered
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novonordisk
11.5.1 Novonordisk Company Details
11.5.2 Company Business Overview
11.5.3 Novonordisk Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Novonordisk Oral Hypoglyceimic Agents (OHAs) Products Offered
11.5.5 Novonordisk Recent Development
11.6 Sanofi-Aventis
11.6.1 Sanofi-Aventis Company Details
11.6.2 Company Business Overview
11.6.3 Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Products Offered
11.6.5 Sanofi-Aventis Recent Development
11.7 Servier
11.7.1 Servier Company Details
11.7.2 Company Business Overview
11.7.3 Servier Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Servier Oral Hypoglyceimic Agents (OHAs) Products Offered
11.7.5 Servier Recent Development
11.8 Huadong Medicine
11.8.1 Huadong Medicine Company Details
11.8.2 Company Business Overview
11.8.3 Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Products Offered
11.8.5 Huadong Medicine Recent Development
11.9 Wanbang Biopharmaceuticals
11.9.1 Wanbang Biopharmaceuticals Company Details
11.9.2 Company Business Overview
11.9.3 Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Products Offered
11.9.5 Wanbang Biopharmaceuticals Recent Development
11.10 Double-Crane Pharmaceutical
11.10.1 Double-Crane Pharmaceutical Company Details
11.10.2 Company Business Overview
11.10.3 Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Products Offered
11.10.5 Double-Crane Pharmaceutical Recent Development
11.11 Guangzhou Pharmaceutical

12 Future Forecast
12.1 Oral Hypoglyceimic Agents (OHAs) Market Forecast by Regions
12.1.1 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Regions 2019-2025
12.1.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue Forecast by Regions 2019-2025
12.2 Oral Hypoglyceimic Agents (OHAs) Market Forecast by Product
12.2.1 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Product 2019-2025
12.2.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue Forecast by Product 2019-2025
12.3 Oral Hypoglyceimic Agents (OHAs) Market Forecast by End User
12.4 North America Oral Hypoglyceimic Agents (OHAs) Forecast
12.5 Europe Oral Hypoglyceimic Agents (OHAs) Forecast
12.6 Asia Pacific Oral Hypoglyceimic Agents (OHAs) Forecast
12.7 Central & South America Oral Hypoglyceimic Agents (OHAs) Forecast
12.8 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Oral Hypoglyceimic Agents (OHAs) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

Choose License Type

Checkout Inquiry Sample